Biogen's Tecfidera continues to gain ground, pick up market share

The market for multiple sclerosis medications is growing ever more crowded, especially with the advent of oral MS drugs, which are grabbing market share. One such pill is Biogen Idec's ($BIIB) Tecfidera, whiched raked in $192 million in sales its first quarter on the market--more than twice what some analysts expected. But Tecfidera is not stopping there. An investor note from Leerink Swann says the drug showed a 4.3% week-over-week increase in new prescriptions for the week ended July 26. While analyst Dr. Marko Kozul cautions that early data "may not be the best of Tecfidera's launch and long-term potential," he also calls the drug's launch "very impressive" overall.